NCT05813925

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or Obesity

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 331 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week. The study medicine will be injected with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1½ years.

Conditions

• Obesity or Overweight

Interventions

Type	Name	Description
DRUG	Cagrilintide	Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
DRUG	Semaglutide	Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
DRUG	Placebo Semaglutide	Participants will receive placebo matched to semaglutide

Timeline

• Start date: 2023-04-03
• Primary completion: 2025-01-17
• Completion: 2025-03-07
• First posted: 2023-04-14
• Last updated: 2026-01-22

Locations

28 sites across 2 countries: Japan, Taiwan

Regulatory

• FDA-regulated drug study